Severe influenza: Clinical features and treatment options

Current Respiratory Medicine Reviews

Volumn 8, Issue 3, 2012, Pages 208-227

  Dunning, Jake ^a   Openshaw, Peter ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Antiviral; H1N1; Influenza; Pandemic; Treatment

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; ANTIBODY; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; DAS 181; FAVIPIRAVIR; FLUDASE; IMMUNOMODULATING AGENT; LANINAMIVIR; LANINAMIVIR OCTANOATE; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

CLINICAL FEATURE; DEATH; DISEASE SEVERITY; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION RISK; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; NONHUMAN; OUTCOMES RESEARCH; PANDEMIC; PHARMACEUTICAL CARE; PREGNANT WOMAN; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; UNITED KINGDOM; WINTER;

EID: 84861134432     PISSN: 1573398X     EISSN: 18756387     Source Type: Journal    
DOI: 10.2174/157339812800493223     Document Type: Review

References (184)

1. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swineorigin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360(25): 2605-15.
2. Morens DM, Taubenberger JK, Harvey HA, Memoli MJ. The 1918 influenza pandemic: lessons for 2009 and the future. Crit Care Med 2010; 38(4 Suppl): e10-20.
3. Campbell CN, Mytton OT, McLean EM, et al. Hospitalization in two waves of pandemic influenza A(H1N1) in England. Epidemiol Infect 2011; 139(10): 1560-9.
4. Donaldson L. A pandemic on the horizon. J R Soc Med 2006; 99(5): 222-5.
5. Osterholm MT. Preparing for the next pandemic. N Engl J Med 2005; 352(18): 1839-42.
6. Kmietowicz Z. WHO declares that H1N1 pandemic is officially over. BMJ 2010; 341: c4393.
7. Miller MA, Viboud C, Balinska M, Simonsen L. The signature features of influenza pandemics--implications for policy. N Engl J Med 2009; 360(25): 2595-8.
8. Seasonal influenza vaccine uptake amongst GP patient groups in England Winter season 2010-11. 2011 [cited 2011 1 November]; Available from: http://www.dh.gov.uk/dr_consum_dh/groups/dh_ digitalassets/documents/digitalasset/dh_129856.pdf.
9. Hardelid P, Andrews NJ, Hoschler K, et al. Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza A/H1N1 2009. Health Technol Assess 2010; 14(55): 115-92.
10. Surveillance of influenza and other respiratory viruses in the UK: 2010-11 report. 2010 [cited 2011 1 November]; Available from: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/129668741 4154.
11. Epidemiological report of pandemic (H1N1) 2009 in the UK. 2010 [cited 2011 1 November]; Available from: http://www.hpa.org.uk/ Publications/InfectiousDiseases/Influenza/1010Epidemiologicalrep ortofpandemicH1N12009inUK.
12. Ellis J, Galiano M, Pebody R, et al. Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11. Euro Surveill 2011; 16(1). pii: 19760.
13. Baillie GJ, Galiano M, Agapow PM, et al. Evolutionary Dynamics of Local Pandemic H1N1/09 Influenza Lineages Revealed by Whole Genome Analysis. J Virol J Virol 2012; 86(1): 11-8.
14. Zakikhany K, Degail MA, Lamagni T, et al. Increase in invasive Streptococcus pyogenes and Streptococcus pneumoniae infections in England, December 2010 to January 2011. Euro Surveill 2011; 16(5). pii: 19785.
15. Dear Colleague Letter: Influenza Season 2010/11-Use of Antivirals (Gateway reference 15274) 2010 [cited 2011 1 November]; Available from: http://www.dh.gov.uk/dr_consum_dh/groups/ dh_digitalassets/documents/digitalasset/dh_122573.pdf.
16. Amantadine, oseltamivir and zanamivir for the treatment of influenza: review of NICE technology appraisal guidance 58. 2010 [cited 2011 01 November]; Available from: http://www.nice.org. uk/nicemedia/live/11774/43268/43268.pdf.
17. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12(10): 1203-7.
18. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 2008; 358(3): 261-73.
19. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005; 353(13): 1374-85.
20. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis 2010; 202(8): 1154-60.
21. Schünemann HJ, Hill SR, Kakad M, et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007; 7(1): 21-31.
22. Paediatric practice note for the management of critically ill children with pandemic (H1N1) 2009 influenza (version 5). 2010 [cited 2011 1 November]; Available from: http://www.hpa.org.uk/webc/ HPAwebFile/HPAweb_C/1287148680698.
23. Pharmacological treatment and prophylaxis of influenza. 2011 [cited 2011 1 November]; Available from: http://www.hpa.org. uk/webc/HPAwebFile/HPAweb_C/1287147812045.
24. Hui DS, Lee N, Chan PK. Clinical management of pandemic 2009 influenza A(H1N1) infection. Chest 2010; 137(4): 916-25.
25. Bautista E, Chotpitayasunondh T, Gao Z, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362(18): 1708-19.
26. Davies A, Jones D, Bailey M, et al. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA 2009; 302(17): 1888-95.
27. Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 2011; 306(15): 1659-68.
28. White DB, Angus DC. Preparing for the Sickest Patients With 2009 Influenza A(H1N1). JAMA 2009; 302(17): 1905-6.
29. Critical care management of adults with influenza with particular reference to (H1N1) 2009. 2010 [cited 2011 2 November]; Available from: http://www.hpa.org.uk/webc/HPAwebFile/HPA web_C/1287148502205.
30. Donaldson LJ, Rutter PD, Ellis BM, et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009; 339: b5213.
31. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 2010; 65(7): 645-51.
32. Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361(20): 1935-44.
33. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361(20): 1945-52.
34. Charu V, Chowell G, Palacio Mejia LS, et al. Mortality Burden of the A/H1N1 Pandemic in Mexico: A Comparison of Deaths and Years of Life Lost to Seasonal Influenza. Clin Infect Dis 2011; 53(10): 985-93.
35. Viboud C, Miller M, Olson D, Osterholm M, Simonsen L. Preliminary Estimates of Mortality and Years of Life Lost Associated with the 2009 A/H1N1 Pandemic in the US and Comparison with Past Influenza Seasons. PLoS Curr 2010: RRN1153.
36. Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302(17): 1872-9.
37. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302(17): 1896-902.
38. Van Kerkhove MD, Vandemaele KA, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8(7): e1001053.
39. Semple M, Lim WS, Myles P, et al. Relationship of asthma to outcome in influenza A / H1N1 2009 infection: FLU-CIN cohort study. Eur Respir J 2011; 38(suppl 55).
40. Ajlan AM, Quiney B, Nicolaou S, Müller NL. Swine-origin influenza A (H1N1) viral infection: radiographic and CT findings. AJR Am J Roentgenol 2009; 193(6): 1494-9.
41. Agarwal PP, Cinti S, Kazerooni EA. Chest radiographic and CT findings in novel swine-origin influenza A (H1N1) virus (S-OIV) infection. AJR Am J Roentgenol 2009; 193(6): 1488-93.
42. McEwen RE, Scriven JE, Green CA, Bailey MS, Banerjee AK. Chest radiography findings in adults with pandemic H1N1 2009 influenza. Br J Radiol 2010; 83(990): 499-504.
43. Intensive-care patients with severe novel influenza A (H1N1) virus infection-Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009; 58(27): 749-52.
44. Gill JR, Sheng ZM, Ely SF, et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010; 134(2): 235-43.
45. Webb SA, Aubron C, Bailey M, et al. Critical care services and the H1N1 (2009) influenza epidemic in Australia and New Zealand in 2010: the impact of the second winter epidemic. Crit Care 2011; 15(3): R143.
46. Dunning J, Openshaw PJ. Impact of the 2009 influenza pandemic. Thorax 2010; 65(6): 471-2.
47. Rowan KM, Harrison DA, Walsh TS, et al. The Swine Flu Triage (SwiFT) study: development and ongoing refinement of a triage tool to provide regular information to guide immediate policy and practice for the use of critical care services during the H1N1 swine influenza pandemic. Health Technol Assess 2010; 14(55): 335-492.
48. Shieh WJ, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010; 177(1): 166-75.
49. Lucas S. Predictive clinicopathological features derived from systematic autopsy examination of patients who died with A/H1N1 influenza infection in the UK 2009-10 pandemic. Health Technol Assess 2010; 14(55): 83-114.
50. Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010; 181(1): 72-9.
51. Gilbert CR, Vipul K, Baram M. Novel H1N1 influenza A viral infection complicated by alveolar hemorrhage. Respir Care 2010; 55(5): 623-5.
52. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006; 12(9): 1023-6.
53. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201(6): 937-47.
54. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198(7): 962-70.
55. Estenssoro E, Ríos FG, Apezteguía C, et al. Pandemic 2009 influenza A in Argentina: a study of 337 patients on mechanical ventilation. Am J Respir Crit Care Med 2010; 182(1): 41-8.
56. Bewick T, Myles P, Greenwood S, et al. Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults. Thorax 2011; 66(3): 247-52.
57. Rothberg MB, Haessler SD. Complications of seasonal and pandemic influenza. Crit Care Med 2010; 38(4 Suppl): e91-7.
58. Cao B, Li XW, Mao Y, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009; 361(26): 2507-17.
59. Davis LE. Neurologic and muscular complications of the 2009 influenza A (H1N1) pandemic. Curr Neurol Neurosci Rep 2010; 10(6): 476-83.
60. Ayala E, Kagawa FT, Wehner JH, Tam J, Upadhyay D. Rhabdomyolysis associated with 2009 influenza A(H1N1). JAMA 2009; 302(17): 1863-4.
61. Gutierrez RL, Ellis MW, Decker CF. Rhabdomyolysis and pandemic (H1N1) 2009 pneumonia in adult. Emerg Infect Dis 2010; 16(3): 565.
62. Chacko B, Peter JV, Pichamuthu K, et al. Cardiac manifestations in patients with pandemic (H1N1) 2009 virus infection needing intensive care. J Crit Care 2012; 27(1): 106. e1-6.
63. Uyeki TM, Prasad R, Vukotich C, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis 2009; 48(9): e89-92.
64. Evaluation of rapid influenza diagnostic tests for detection of novel influenza A (H1N1) Virus-United States, 2009. MMWR Morb Mortal Wkly Rep 2009; 58(30): 826-9.
65. Clinical management of human infection with pandemic (H1N1) 2009: revised guidance. 2009 [cited 2011 2 November]; Available from: http://www.who.int/csr/resources/publications/swineflu/clini cal_management/en/index.html.
66. Sambol AR, Iwen PC, Pieretti M, et al. Validation of the Cepheid Xpert Flu A real time RT-PCR detection panel for emergency use authorization. J Clin Virol 2010; 48(4): 234-8.
67. Sanghavi SK, Bullotta A, Husain S, Rinaldo CR. Clinical evaluation of multiplex real-time PCR panels for rapid detection of respiratory viral infections. J Med Virol 2011.
68. Nolte FS. Molecular diagnostics for detection of bacterial and viral pathogens in community-acquired pneumonia. Clin Infect Dis 2008; 47 Suppl 3: S123-6.
69. Uyeki T. Diagnostic testing for 2009 pandemic influenza A (H1N1) virus infection in hospitalized patients. N Engl J Med 2009; 361(25): e114.
70. Rello J, Rodríguez A, Ibañez P, et al. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care 2009; 13(5): R148.
71. Singh K, Vasoo S, Stevens J, Schreckenberger P, Trenholme G. Pitfalls in diagnosis of pandemic (novel) A/H1N1 2009 influenza. J Clin Microbiol 2010; 48(4): 1501-3.
72. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl 3: iii1-55.
73. Rahman M, Bright RA, Kieke BA, et al. Adamantane-resistant influenza infection during the 2004-05 season. Emerg Infect Dis 2008; 14(1): 173-6.
74. Deyde VM, Sheu TG, Trujillo AA, et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 2010; 54(3): 1102-10.
75. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325(5937): 197-201.
76. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008; 78(1): 91-102.
77. WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses 2010 [cited 2011 2 November]; Available from: http://www.who.int/csr/resour ces/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.
78. Swine flu clinical package for use when there are exceptional demands on healthcare services 2009 [cited 2011 02 November]; Available from: http://www.dh.gov.uk/prod_consum_ dh/groups/dh_digitalassets/@dh/@en/@ps/@sta/@perf/documents/ digitalasset/dh_107600.pdf.
79. Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48 Suppl 1: S3-13.
80. McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis 2007; 45(12): 1568-75.
81. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12(4): 501-8.
82. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200(4): 492-500.
83. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009; 339: b5106.
84. Lee N, Chan PK, Lui GC, et al. Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? J Infect Dis 2011; 203(12): 1739-47.
85. Domínguez-Cherit G, Namendys-Silva SA, de la Torre A, Macias AE, Cordova-Villalobos JA. H1N1 Influenza Pandemic of 2009 Compared With Other Influenza Pandemics: Epidemiology, Diagnosis, Management, Pulmonary Complications, and Outcomes. Curr Infect Dis Rep 2010; 12(3): 204-10.
86. Smith JR. Oseltamivir in human avian influenza infection. J Antimicrob Chemother 2010; 65 Suppl 2: ii25-ii33.
87. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012; 1: CD008965.
88. Hernán MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53(3): 277-9.
89. Team CNIR. Does oseltamivir really reduce complications of influenza? Clin Infect Dis. 2011; 53(12): 1302-3; author reply 3-4.
90. Reddy D. Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir. J Antimicrob Chemother 2010; 65 Suppl 2: ii35-ii40.
91. Influenza Season 2010/11-Use of Antivirals (Dear Colleague Letter, Gateway Reference 15274). 2010 [cited 2011 2 November]; Available from: http://www.dh.gov.uk/prod_consum_dh/groups/ dh_digitalassets/documents/digitalasset/dh_122573.pdf.
92. 2010/11 seasonal influenza: prescription of antivirals-letter from the CMO (Dear Colleague Letter, Gateway Reference 15338). [cited 2011 1 November]; Available from: http://www.dh.gov.uk/ prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/dig italasset/dh_123094.pdf.
93. Domínguez-Cherit G, Lapinsky SE, Macias AE, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302(17): 1880-7.
94. Lee N, Cockram CS, Chan PK, et al. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis 2008; 46(8): 1323-4.
95. UK Influenza Pandemic Preparedness Strategy 2011 2011 [cited 2011 10 November]; Available from: http://www.dh.gov.uk/ prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/d h_131040.pdf.
96. Dutkowski R. Oseltamivir in seasonal influenza: cumulative experience in low-and high-risk patients. J Antimicrob Chemother 2010; 65 Suppl 2: ii11-ii24.
97. Falagas ME, Vouloumanou EK, Baskouta E, et al. Treatment options for 2009 H1N1 influenza: evaluation of the published evidence. Int J Antimicrob Agents 2010; 35(5): 421-30.
98. Hien TT, Boni MF, Bryant JE, et al. Early pandemic influenza (2009 H1N1) in Ho Chi Minh City, Vietnam: a clinical virological and epidemiological analysis. PLoS Med 2010; 7(5): e1000277.
99. Ling LM, Chow AL, Lye DC, et al. Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50(7): 963-9.
100. To KK, Hung IF, Li IW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50(6): 850-9.
101. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ 2010; 341: c4779.
102. Zarychanski R, Stuart TL, Kumar A, et al. Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010; 182(3): 257-64.
103. Siston AM, Rasmussen SA, Honein MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010; 303(15): 1517-25.
104. Lackenby A, Moran Gilad J, Pebody R, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill 2011; 16(5). pii: 19784.
105. Dutkowski R, Thakrar B, Froehlich E, et al. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003; 26(11): 787-801.
106. Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother 2010; 65 Suppl 2: ii5-ii10.
107. Human Medicines: Tamiflu (oseltamivir). 2011 [cited 2011 2 November]; Available from: http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/000402/human_med_0 01075.jsp&mid=WC0b01ac058001d124.
108. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999; 37(6): 471-84.
109. CHMP Assessment Report on novel influenza (H1N1) outbreak: Tamiflu (oseltamivir); Relenza (zanamivir). 2009; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/20 09/12/WC500018448.pdf.
110. Greer LG, Leff RD, Rogers VL, et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol 2011; 204(6 Suppl 1): S89-93.
111. Beigi RH, Han K, Venkataramanan R, et al. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol 2011; 204(6 Suppl 1): S84-8.
112. Wattanagoon Y, Stepniewska K, Lindegårdh N, et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 2009; 53(3): 945-52.
113. Zhu HJ, Patrick KS, Yuan HJ, et al. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 2008; 82(6): 1241-8.
114. Zhu HJ, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos 2009; 37(2): 264-7.
115. L'Huillier AG, Ing Lorenzini K, Crisinel PA, et al. ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivirtreated children during influenza H1N1/09 pandemia. Pharmacogenomics 2011; 12(10): 1493-501.
116. Howton JC. Probenecid with oseltamivir for human influenza A (H5N1) virus infection? N Engl J Med 2006; 354(8): 879-80.
117. Holodniy M, Penzak SR, Straight TM, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 2008; 52(9): 3013-21.
118. Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010; 182(4): 357-63.
119. Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008; 31(12): 1097-114.
120. Toovey S. Influenza-associated central nervous system dysfunction: a literature review. Travel Med Infect Dis 2008; 6(3): 114-24.
121. Smith JR, Rayner CR, Donner B, et al. Oseltamivir in seasonal, pandemic, and avian influenza: a comprehensive review of 10-years clinical experience. Adv Ther 2011; 28(11): 927-59.
122. Summary on compassionate use for Tamiflu IV. 2011 [cited 2011 02 November]; Available from: http://www.ema.europa.eu/docs/ en_GB/document_library/Other/2010/05/WC500090250.pdf.
123. Fleury H, Burrel S, Balick Weber C, et al. Prolonged shedding of influenza A(H1N1)v virus: two case reports from France 2009. Euro Surveill 2009; 14(49). pii: 19434.
124. Lee N, Chan PK, Wong CK, et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2011; 16(2): 237-47.
125. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitorresistant variants. Antimicrob Agents Chemother 2001; 45(12): 3403-8.
126. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15(4): 552-60.
127. Summary of influenza antiviral susceptibility surveillance findings, September 2010-March 2011. 2011 [cited 2011 3 November]; Available from: http://www.who.int/influenza/gisrs_laboratory/ updates/antiviral_susceptibility/en/.
128. Hurt AC, Lee RT, Leang SK, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011; 16(23). pii: 19884.
129. Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet. 1999; 36 Suppl 1: 1-11.
130. Summary of Product Characteristics: Relenza 5mg/dose inhalational powder. [cited 2011 November]; Available from: http://www.medicines.org.uk/emc/medicine/2608/SPC/Relenza+5 mg+dose+inhalation+powder./#CLINICAL_PRECAUTIONS.
131. Dear Doctor Letter: Relenza (zanamivir) inhalation powder must not be dissolved for administration via nebuliser. 2009 [cited 2011 04 November]; Available from: https://www.cas.dh.gov.uk/View andAcknowledgment/ViewAlert.aspx?AlertID=101276.
132. Da Dalt L, Calistri A, Chillemi C, et al. Oseltamivir-resistant pandemic (H1N1) 2009 treated with nebulized zanamivir. Emerg Infect Dis 2010; 16(11): 1813-5.
133. Personal communication with GlaxoSmithKline plc. Zanamivir aqueous solution-Request for data. 2011.
134. Conditions of use, conditions for distribution and patients targeted and conditions for safety monitoring adressed to member states for IV Zanamivir available for compassionate use. 2011 [cited 2011 04 November]; Available from: http://www.ema.europa.eu/docs/en_ GB/document_library/Other/2010/02/WC500074124.pdf.
135. GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza. 2011 [cited 2011 November 05]; Available from: http://www.gsk.com/media/ pressreleases/2011/2011_pressrelease_10015.htm.
136. Kidd IM, Down J, Nastouli E, et al. H1N1 pneumonitis treated with intravenous zanamivir. Lancet 2009; 374(9694): 1036.
137. Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010; 50(11): 1493-6.
138. Speers DJ, Williams SH, Pinder M, et al. Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. Med J Aust 2010; 192(3): 166-8.
139. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010; 362(1): 88-9.
140. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivirresistant influenza viruses with a novel neuraminidase mutation. J Virol 2009; 83(20): 10366-73.
141. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009; 58(35): 969-72.
142. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010; 51(8): 983-4.
143. van der Vries E, Stelma FF, Boucher CA. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010; 363(14): 1381-2.
144. Inc. BP. Peramivir (Neuraminidase Inhibitor). 2011 [cited 2011 3 November]; Available from: http://www.biocryst.com/peramivir.
145. Je H, editor. Peramivir advanced clinical development update. XII International Symposium Respiratory Viral Infections; 2010; Taipei, Taiwan.
146. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res 2007; 74(2): 159-62.
147. Yamashita M, Tomozawa T, Kakuta M, et al. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 2009; 53(1): 186-92.
148. Sugaya N. Oral presentation. XIV International Symposium on Respiratory Viral Infections; 26 March 2012; Istanbul, Turkey2012.
149. Smee DF, Hurst BL, Wong MH, et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 2010; 54(1): 126-33.
150. Boltz DA, Aldridge JR, Webster RG, Govorkova EA. Drugs in development for influenza. Drugs 2010; 70(11): 1349-62.
151. Belser JA, Lu X, Szretter KJ, et al. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J Infect Dis 2007; 196(10): 1493-9.
152. Chan RW, Chan MC, Wong AC, et al. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob Agents Chemother 2009; 53(9): 3935-41.
153. Triana-Baltzer GB, Gubareva LV, Nicholls JM, et al. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS One 2009; 4(11): e7788.
154. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7(11): e1000362.
155. Petersen E, Keld DB, Ellermann-Eriksen S, et al. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator-and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis 2011; 43(6-7): 495-503.
156. Nguyen JT, Hoopes JD, Smee DF, et al. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother 2009; 53(10): 4115-26.
157. Renaud C, Boudreault AA, Kuypers J, et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 2011; 17(4): 653-60; quiz 765.
158. Kim WY, Young Suh G, Huh JW, et al. Triple-Combination Antiviral Drug for Pandemic H1N1 Influenza Virus Infection in Critically Ill Patients on Mechanical Ventilation. Antimicrob Agents Chemother 2011; 55(12): 5703-9.
159. Viasus D, Paño-Pardo JR, Cordero E, et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011; 62(3): 193-9.
160. Fedson DS. Pandemic influenza: a potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006; 43(2): 199-205.
161. Fedson DS. Confronting the next influenza pandemic with antiinflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3(4): 129-42.
162. Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. PPARgamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol 2010; 23(4): 343-52.
163. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 2008; 8(9): 571-6.
164. Savarino A. Use of chloroquine in viral diseases. Lancet Infect Dis 2011; 11(9): 653-4.
165. Lauder SN, Taylor PR, Clark SR, et al. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 2011; 66(5): 368-74.
166. Tran TH, Ruiz-Palacios GM, Hayden FG, Farrar J. Patient-oriented pandemic influenza research. Lancet 2009; 373(9681): 2085-6.
167. Walley T, Davidson P, Davison P. Research funding in a pandemic. Lancet 2010; 375(9720): 1063-5.
168. Viboud C, Tam T, Fleming D, Miller MA, Simonsen L. 1951 influenza epidemic, England and Wales, Canada, and the United States. Emerg Infect Dis 2006; 12(4): 661-8.
169. Minneci PC, Deans KJ, Eichacker PQ, Natanson C. The effects of steroids during sepsis depend on dose and severity of illness: an updated meta-analysis. Clin Microbiol Infect 2009; 15(4): 308-18.
170. Annane D, Bellissant E, Bollaert PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301(22): 2362-75.
171. Meduri GU, Marik PE, Chrousos GP, et al. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008; 34(1): 61-9.
172. Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008; 336(7651): 1006-9.
173. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol 2010; 9(3): 254-63.
174. Brouwer MC, McIntyre P, de Gans J, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 2010(9): CD004405.
175. Brun-Buisson C, Richard JC, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183(9): 1200-6.
176. Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183(9): 1207-14.
177. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145(8): 599-609.
178. Hanson BJ, Boon AC, Lim AP, et al. Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 2006; 7: 126.
179. Friesen RH, Koudstaal W, Koldijk MH, et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS One 2010; 5(2): e9106.
180. Koudstaal W, Koldijk MH, Brakenhoff JP, et al. Pre-and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir. J Infect Dis 2009; 200(12): 1870-3.
181. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52(4): 447-56.
182. Implementation of the International Health Regulations (2005). Report of the Review Committee on the Functioning of the International Health Regulations (2005) in relation to Pandemic (H1N1) 2009.2011. Available from: http://apps.who.int/gb/eb wha/pdf_files/WHA64/A64_10-en.pdf.
183. WHO Public Health Research Agenda for Influenza (Version 1)2009. Available from: http://www.who.int/influenza/resources/ research/2010_04_29_global_influenza_research_agenda_version_ 01_en.pdf.
184. New international consortium to prepare research community for future pandemics. 2011 [cited 2012 01 March]; Available from: http://www.wellcome.ac.uk/News/Media-office/ Pressreleases/ 2011/WTVM053638.htm